Tags

Type your tag names separated by a space and hit enter

Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
Cancer Epidemiol Biomarkers Prev. 2003 Nov; 12(11 Pt 1):1209-12.CE

Abstract

The lignan enterolactone, produced by the intestinal microflora from dietary precursors, has been hypothesized to protect against hormone-dependent cancers and cardiovascular diseases. We conducted a nested case-control study to examine the relationship between serum enterolactone concentration and prostate cancer. Enterolactone concentrations were measured by time-resolved fluoroimmunoassay in serum collected at baseline in the alpha-Tocopherol, beta-Carotene Cancer Prevention Study from 214 men with prostate cancer diagnosed during a 6-year follow-up and from 214 controls matched by age, date of baseline blood collection, intervention group, and local study area. Mean serum enterolactone concentration (in nmol/liter) did not differ significantly between case and control subjects [15.9 (SD, 15.2) versus 16.9 (SD, 14.9), respectively (P = 0.42)]. Odds ratios for prostate cancer risk estimated by conditional logistic regression for increasing quartiles of enterolactone concentration were 1.00 (referent), 0.72 [95% confidence interval (CI), 0.43-1.23], 0.98 (95% CI, 0.58-1.68), and 0.71 (95% CI, 0.42-1.21). Our findings do not support the hypothesis that enterolactone is involved in the development of prostate cancer.

Authors+Show Affiliations

National Public Health Institute, Department of Epidemiology and Health Promotion, Helsinki, Finland. annamari.kilkkinen@ktl.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

14652283

Citation

Kilkkinen, Annamari, et al. "Serum Enterolactone Concentration Is Not Associated With Prostate Cancer Risk in a Nested Case-control Study." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 12, no. 11 Pt 1, 2003, pp. 1209-12.
Kilkkinen A, Virtamo J, Virtanen MJ, et al. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2003;12(11 Pt 1):1209-12.
Kilkkinen, A., Virtamo, J., Virtanen, M. J., Adlercreutz, H., Albanes, D., & Pietinen, P. (2003). Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 12(11 Pt 1), 1209-12.
Kilkkinen A, et al. Serum Enterolactone Concentration Is Not Associated With Prostate Cancer Risk in a Nested Case-control Study. Cancer Epidemiol Biomarkers Prev. 2003;12(11 Pt 1):1209-12. PubMed PMID: 14652283.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study. AU - Kilkkinen,Annamari, AU - Virtamo,Jarmo, AU - Virtanen,Mikko J, AU - Adlercreutz,Herman, AU - Albanes,Demetrius, AU - Pietinen,Pirjo, PY - 2003/12/4/pubmed PY - 2004/3/17/medline PY - 2003/12/4/entrez SP - 1209 EP - 12 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 12 IS - 11 Pt 1 N2 - The lignan enterolactone, produced by the intestinal microflora from dietary precursors, has been hypothesized to protect against hormone-dependent cancers and cardiovascular diseases. We conducted a nested case-control study to examine the relationship between serum enterolactone concentration and prostate cancer. Enterolactone concentrations were measured by time-resolved fluoroimmunoassay in serum collected at baseline in the alpha-Tocopherol, beta-Carotene Cancer Prevention Study from 214 men with prostate cancer diagnosed during a 6-year follow-up and from 214 controls matched by age, date of baseline blood collection, intervention group, and local study area. Mean serum enterolactone concentration (in nmol/liter) did not differ significantly between case and control subjects [15.9 (SD, 15.2) versus 16.9 (SD, 14.9), respectively (P = 0.42)]. Odds ratios for prostate cancer risk estimated by conditional logistic regression for increasing quartiles of enterolactone concentration were 1.00 (referent), 0.72 [95% confidence interval (CI), 0.43-1.23], 0.98 (95% CI, 0.58-1.68), and 0.71 (95% CI, 0.42-1.21). Our findings do not support the hypothesis that enterolactone is involved in the development of prostate cancer. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/14652283/Serum_enterolactone_concentration_is_not_associated_with_prostate_cancer_risk_in_a_nested_case_control_study_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=14652283 DB - PRIME DP - Unbound Medicine ER -